Mary E. Fox
Impact in
- Biotechnology top 5%
- Cancer Research and Treatments
- Toxicology top 5%
Papers in
-
- Bioactive Compounds and Antitumor Agents 4
-
- Cancer Research and Treatments 3
- Co-authors
- Gerald R. Smith (5 shared papers)Peter J. Smith (1 shared paper)J. Martin Brown (2 shared papers)Nigel Peter Minton (3 shared papers)Paul J. Smith (2 shared papers)Marilyn J. Lemmon (2 shared papers)James E. M. Watson (1 shared paper)Gilbert Chu (1 shared paper)
- Journals
- Genetics (3 papers)Molecular and Cellular Biology (1 paper)Proceedings of the National Academy of Sciences (1 paper)Cancer Chemotherapy and Pharmacology (1 paper)Biochemical Pharmacology (1 paper)
- Partner nations
- United StatesUnited KingdomJapan
In The Last Decade
Mary E. Fox
14 papers receiving 622 citations
Peers
Comparison fields: 5 of 63
- Biotechnology 157
- Toxicology 35
- Molecular Biology 412
- Genetics 127
- Cancer Research 56
Countries citing papers authored by Mary E. Fox
This map shows the geographic impact of Mary E. Fox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary E. Fox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary E. Fox more than expected).
Fields of papers citing papers by Mary E. Fox
This network shows the impact of papers produced by Mary E. Fox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary E. Fox. The network helps show where Mary E. Fox may publish in the future.
Co-authors
The 25 scholars most cited alongside Mary E. Fox, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. | 1996 | 140 |
| 2 | Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone. | 1990 | 75 |
| 3 | 1995 | 70 | |
| 4 | 1990 | 66 | |
| 5 | Subcellular distribution of the anticancer drug mitoxantrone in human and drug-resistant murine cells analyzed by flow cytometry and confocal microscopy and its relationship to the induction of DNA damage. | 1992 | 49 |
| 6 | 1994 | 43 | |
| 7 | 1998 | 43 | |
| 8 | 2000 | 41 | |
| 9 | 1997 | 40 | |
| 10 | 2001 | 31 | |
| 11 | 1997 | 28 | |
| 12 | 1995 | 18 | |
| 13 | Investigations into the lymphopaenic and immunosuppressive properties of the antitumour agent, mitoclomine. | 1971 | 4 |
| 14 | 2003 | 2 |
About Mary E. Fox
Mary E. Fox is a scholar working on Toxicology, Biotechnology, Molecular Biology, Genetics and Organic Chemistry, having authored 14 papers that have together received 650 indexed citations. Recurring topics across this work include DNA Repair Mechanisms (7 papers), Fungal and yeast genetics research (5 papers), Bioactive Compounds and Antitumor Agents (4 papers), Cancer therapeutics and mechanisms (4 papers), Cancer Research and Treatments (3 papers), Photosynthetic Processes and Mechanisms (2 papers), Genomics and Chromatin Dynamics (2 papers) and Light effects on plants (1 paper). The work is most often cited by research in Biotechnology (157 citations), Toxicology (35 citations), Molecular Biology (412 citations), Genetics (127 citations) and Cancer Research (56 citations). Mary E. Fox has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Gerald R. Smith, Peter J. Smith, J. Martin Brown, Nigel Peter Minton, Paul J. Smith, Marilyn J. Lemmon, James E. M. Watson, Gilbert Chu, Brian J. Feldman and Kunihiro Ohta. Their work appears in journals such as Genetics, Molecular and Cellular Biology, Proceedings of the National Academy of Sciences, Cancer Chemotherapy and Pharmacology and Biochemical Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.